Skip to content

Middle East Pharmaceutical Industries Company vs Jamjoom Pharmaceuticals Factory Co.

A head-to-head of Middle East Pharmaceutical Industries Company (4016) and Jamjoom Pharmaceuticals Factory Co. (4015) across valuation, profitability, growth, and dividends. Green marks the more favourable value on that metric only — not a recommendation.

Metric40164015
Market Cap2.06B SAR11.05B SAR
P/E (TTM)12.4622.16
Forward P/E11.57
P/S4.197.25
P/B5.075.95
EV/EBITDA9.5920.41
Dividend Yield2.39%253.00%
Profit Margin21.19%31.16%
Gross Margin62.29%62.56%
Operating Margin23.74%31.82%
Revenue Growth (YoY)+33.65%+5.21%
FCF Yield1.62%2.33%
Debt / Equity19.871.20
Current Ratio2.854.94

Which is better: Middle East Pharmaceutical Industries Company or Jamjoom Pharmaceuticals Factory Co.?

  • Larger by market cap: Jamjoom Pharmaceuticals Factory Co.
  • Cheaper valuation (lower P/E): Middle East Pharmaceutical Industries Company
  • Higher dividend yield: Jamjoom Pharmaceuticals Factory Co.
  • More profitable (net margin): Jamjoom Pharmaceuticals Factory Co.
  • Faster revenue growth: Middle East Pharmaceutical Industries Company
  • Higher free-cash-flow yield: Jamjoom Pharmaceuticals Factory Co.

Across 12 available metrics, Jamjoom Pharmaceuticals Factory Co. leads 7–5.

There's no single "better" — it depends on your goal: income investors may prefer the higher yield, growth investors the faster grower, and value investors the cheaper one. See each stock's page for deeper detail. This is an automated read, not a recommendation.

Share:

Compare Middle East Pharmaceutical Industries Company with others

This comparison is for informational and educational purposes only, based on available data — not a recommendation to buy or sell any stock.